ArticleSkin health and disease2025
Gut barrier integrity disruption in atopic dermatitis: truth or myth-a case-control study.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Probiotic lactic acid bacterial strains MG4693 and MG5474 alleviate atopic dermatitis by enhancing intestinal barrier integrity and modulating the immune system.Food & nutrition research · 2026Article
- Severity of atopic dermatitis is associated with gut-derived metabolites and leaky gut-related biomarkers.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut dysbiosis has been linked to the onset and progression of various diseases, including atopic dermatitis, by disrupting the intestinal barrier integrity. In turn, it allows the translocation of microbes and toxins into the systemic circulation, which triggers an immune response. Objectives: To measure serum levels of the gut integrity markers claudin 3 and intestinal fatty acid-binding protein in patients with atopic dermatitis. Methods: This prospective study was conducted on 43 patients with atopic dermatitis. Healthy volunteers ( Results: There were no significant differences in serum levels of claudin 3 and intestinal fatty acid-binding protein between patients with atopic dermatitis and the control group ( Conclusion: Alterations in the intestinal barrier may be absent in the ethnically distinct group of patients with atopic dermatitis included in our study. Nevertheless, our findings might have been influenced by factors such as the duration of the disease, diet and characteristics of the study population. Further studies are needed to investigate additional biomarkers or mechanisms that may be involved in atopic dermatitis pathogenesis, especially those related to the gut-skin axis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.